Abstract
No public abstract is available from the verified source records.
Paola Gargiulo, Federica Marzano, Laura Liccardi, Savina Nodari, Matteo Cameli, Francesco Giallauria, Federico Guerra, Egidio Imbalzano, Gianfranco Sinagra, Stefano Carugo, Francesco Cipollone, Francesco Grigioni, Saverio Muscoli, Alberto Polimeni, Pasquale Perrone Filardi, Ciro Indolfi, Mario Crisci, Claudio Ferri, Scipione Carerj, Ferdinando Varbella, Gennaro Galasso, Piergiuseppe Agostoni, Giuseppe Patti, Natale Daniele Brunetti, Giovanni Barbati, Alfredo Ruggero Galassi, Stefania Marazia, Antonio Cittadini, Giovanni Esposito, Stefania Paolillo, Mattia Amarante, Luca Assoni, Matilde Lombardi, Gianluigi Cuomo, Giulia Stronati, Marianna Gigliotti De Fazio, Maddalena Rossi, Andrea Faggiano, Damiano Fedele, Damiano D'Ardes, Ilaria Cavallari, Giuseppe Massimo Sangiorgi, Rossella Quarta, Arturo Cesaro, Gianluca Baldini, Giancarlo Trimarchi, Antonella Corleto, Silvia Tanda, Michele Bellino, Elisabetta Salvioni, Alessandra Marengo, Federica Santagata, Cristina Madaudo, Alberto Maria Marra, Costantino Mancusi, Ilaria Fucile, Ciro Cotticelli, Giuseppe Maria Abbellito, Marco Criscuolo, Antonio Luca Maria Parlati, Isabel Martone, Fabrizio Perrone Filardi
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The lancet commission on diabetes: using data to transform diabetes care and patient lives
10.1016/s0140-6736(20)32374-6 · 2020
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
10.1016/s0140-6736(10)60484-9 · 2010
Association of cardiometabolic multimorbidity with mortality
10.1001/jama.2015.7008 · 2015
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes
10.1093/eurheartj/ehad192 · 2023
Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' Expert forum
10.2337/dci17-0057 · 2018
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
10.1093/eurheartj/ehaa082 · 2020
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
10.1001/jamacardio.2020.4511 · 2021
10-year cardiovascular risk estimation in type 2 diabetes in Europe
10.1093/eurheartj/ehad260 · 2023
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
10.1186/s12933-021-01344-0 · 2021
World medical association declaration of helsinki: ethical principles for medical research involving human subjects
10.1001/jama.2013.281053 · 2013
Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis
10.1186/s12933-026-03215-y · 2026
Effects of dapagliflozin on mortality across the spectrum of cardiovascular-kidney-metabolic syndrome: a meta-analysis
10.1016/j.numecd.2025.104366 · 2026
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
10.1016/s2213-8587(24)00155-4 · 2024
Cardiovascular disease and risk management: standards of care in diabetes—2026
2025
Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis
10.1186/s40842-025-00251-7 · 2025
CAPTURE: a cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy
10.1016/j.numecd.2022.01.026 · 2022
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1812389 · 2019
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
10.1016/s0140-6736(19)31149-3 · 2019
Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis
10.1161/circulationaha.124.071689 · 2024
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study
10.1016/s2666-7568(23)00164-2 · 2023
Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study
10.1186/s12933-022-01713-3 · 2022
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
10.1056/nejmoa1504720 · 2015
Liraglutide and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1603827 · 2016
Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR® Research to practice project
10.1177/2047487317729252 · 2017
Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men
10.1111/dom.13876 · 2020
Effects of Liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial
10.1001/jama.2016.10260 · 2016
Dapagliflozin in patients with chronic kidney disease
10.1056/nejmoa2024816 · 2020
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · 2023
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
10.1056/nejmoa1811744 · 2019
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
10.1056/nejmoa2403347 · 2024
2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-Kidney-Metabolic Syndrome: a report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines
10.1161/cir.0000000000001453 · 2026
No additional external references are available.